Ocular comorbidities are common in atopic dermatitis (AD) as the result of the disease itself or the use of medication. No large-scale epidemiologic data exist on the prevalence of ocular comorbidities in adults with AD.
We sought to examine the prevalence and risk of selected ocular comorbidities in adult patients with AD.
All Danish individuals ≥18 years of age were linked in nationwide registries. Adjusted hazard ratios (HRs) were estimated by means of Cox regression.
A total of 5766 and 4272 adults were categorized as having mild and severe AD, respectively. At least 1 prescription of anti-inflammatory ocular agents was claimed in 12.0% and 18.9% of patients with mild and severe AD, respectively. In adjusted analysis, the HR of conjunctivitis was 1.48 (95% confidence interval [CI], 1.15-1.90) for mild AD and 1.95 (95% CI, 1.51-2.51) for severe AD. The HR of keratitis was 1.66 (95% CI, 1.15-2.40) for mild AD and 3.17 (95% CI, 2.31-4.35) for severe AD. For adults with severe AD, the HR for keratoconus was 10.01 (95% CI, 5.02-19.96). AD was associated with “cataract only” in individuals <50 years of age.
A limitation of the study is that observational studies cannot establish causality.
Adults with AD had a significant and disease severity–dependent increased risk of development of conjunctivitis, keratitis, and keratoconus compared with that of the general population.Le texte complet de cet article est disponible en PDF.
Key words : atopic dermatitis, conjunctivitis, epidemiology, ocular, prevalence, risk
Abbreviations used : AD, AKC, CI, HR, ICD, IL, OR, VKC
| Dr Thyssen is supported by an unrestricted grant from the Lundbeck Foundation, has attended an advisory board for Roche and Sanofi-Genzyme, and has been a speaker on atopic dermatitis for LEO Pharma. Dr Toft and Anne-Sofie Halling-Overgaard have no conflicts of interest. Dr Gislason is supported by an unrestricted research scholarship from the Novo Nordisk Foundation. Dr Skov has received consultancy and/or speaker honoraria from Abbvie, Pfizer, Janssen-Cilag, Merck Sharp & Dohme, and Leo Pharma and is a member of the advisory boards of Abbvie, Pfizer, Janssen-Cilag, Merck Sharp & Dohme, Eli Lilly, Celgene, and Novartis. Dr Egeberg has received research funding from Pfizer and Eli Lilly and honoraria as consultant and/or speaker from Pfizer, Eli Lilly, Novartis, Galderma, and Janssen Pharmaceuticals.
| Conflicts of interest: The authors have no conflicts of interest to declare.